Fast Five Quiz: Interstitial Lung Disease Progressive Fibrosing Management

Zab Mosenifar, MD


February 01, 2022

Antifibrotic therapies should be considered when patients on immunosuppressant therapy begin to develop either progressive changes pathophysiologically or on imaging that suggest fibrosis are likely to benefit from antifibrotic therapy. These therapies should also be considered when there is a strong suspicion that the patient has a PF-ILD pattern.

In older patients with imaging suggesting progression and biopsy of the lung is not possible, antifibrotic use should be considered early in the course of therapy.

Learn more about medication for PF-ILD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.